news Scientists establish genetic link between HLA and genital warts 7 October 2021 | By Anna Begley (Drug Target Review) The discovery of a link between the human leukocyte antigen (HLA) and genital warts may lead to mRNA-based vaccines against HPV and other diseases.
news “Ultrasensitive” HPV detection paves way for precision treatment 28 September 2021 | By Anna Begley (Drug Target Review) A new study sequenced tumour DNA for the “ultrasensitive” detection of HPV, further honing precision treatment of the illness.
news First patient-derived organoid model for cervical cancer developed 15 April 2021 | By Victoria Rees (Drug Target Review) Novel organoid models of cervical cancer and a healthy human cervix have been developed to study the condition and its progression.
news CD47 blockade could work as immunotherapy across multiple diseases 24 June 2020 | By Victoria Rees (Drug Target Review) Researchers have demonstrated that blocking CD47-mediated signalling in mice can enhance the speed of pathogen clearance, presenting a new potential form of immunotherapy.
article Why invest in creating a modifiable drug framework? 27 February 2020 | By Hannah Balfour (Drug Target Review) Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
news E6/Myc binding provides potential treatment strategy for HPV 2 October 2017 | By Dr Zara Kassam (Drug Target Review) A study that teases apart the biological mechanisms by which HPV cause cancer, has found a strategy that may provide targeted treatment...
news Artes and BioSun to co-develop on HPV vaccine 4 November 2016 | By Niamh Louise Marriott, Digital Content Producer The agreed long-term collaboration will take strengths from both companies to collaborate on the HPV vaccine although financial details of this agreement...
news Hookipa receives €4.16 million cancer grant from FFG 18 October 2016 | By Niamh Louise Marriott, Digital Content Producer The grant for the second year of a multi-year R+D project and will be used for Hookipa’s arenaviral vector technologies, cancer immunotherapies and to...